Editas Medicine Announces Transition of Chief Scientific Officer
Editas Medicine Announces Transition of Chief Scientific Officer
CAMBRIDGE, Mass., Jan. 11, 2021 Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that its Chief Scientific Officer, Charles Albright, Ph.D., is stepping down from the Company on January 15 to pursue another opportunity. A search is underway to find a successor to Dr. Albright.
“On behalf of the entire Editas team, I sincerely thank Charlie for his many contributions in pioneering the field of genomic medicine. Charlie has been instrumental in building our scientific organization, defining our programs, and advancing our pipeline. We wish him all the best as he pursues his new role,” said Cindy Collins, President and Chief Executive Officer, Editas Medicine.